Download the MMV-supported projects slide ⁄ Download the Global Portfolio of Antimalarial Medicines slide
For more information about the global malaria portfolio, read the article: Malaria medicines: a glass half full?
See the growth of the MMV portfolio since 2000.
Detailed information is available for translational, development and access projects (click on the boxes below).
Last updated April 2018 (status of tafenoquine & Strides Shasun rectal artesunate updated September 2018)
MMV support to projects may include financial, in-kind, and advisory activities.
Global Fund Expert Review Panel (ERP) reviewed product – permitted for time-limited procurement, while regulatory/WHO prequalification review is ongoing.
Included in MMV portfolio after product approval and/or development. DNDi and partners completed development and registration of ASMQ and ASAQ.
WHO Prequalified OR approved/positive opinion by regulatory bodies who are ICH members/observers.
Paediatric formulation.
1 Coartem® Dispersible
2 Artesun®
3 Eurartesim®
4 Pyramax® tablets or granules
5 ASAQ Winthrop®
6 SPAQ-COTM
7 Krintafel/Kozenis (Trademarks owned or licensed by GSK)
____ 3-day cure, artemisinin-based combination therapies
____ Combinations aiming at a new single-exposure radical cure (SERC) TPP-1
____ Severe malaria treatment and pre-referral intervention
____ Intermittent /seasonal malaria chemoprevention
____ Products targeting prevention of relapse for P. vivax
____ Single-exposure chemoprotection (SEC) TPP-2
Asexual blood stages
Relapse prevention
Transmission reduction
Chemoprotection